PHARMACEUTICAL COMPOSITION FOR IMPROVEMENT OF LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH PROSTATIC HYPERTROPHY

摘要

Disclosed is a pharmaceutical composition comprising (R)-5-(2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl)-2-methoxybenzene-1-sulfonamide (tamsulosin) or a pharmaceutically acceptable salt thereof and (1S)-1-phenyl-1,2,3,4-tetrahydroiso-quinoline-2-carboxylate (3R)-quinuclidin-3-yl ester (solifenacin) or a pharmaceutically acceptable salt thereof as active ingredients, particularly a pharmaceutical composition for ameliorating a lower urinary tract symptom associated with prostatomegaly. Also disclosed is use of a combination of tamsulosin or a pharmaceutically acceptable salt thereof and solifenacin or a pharmaceutically acceptable salt thereof for the amelioration of a lower urinary tract symptom associated with prostatomegaly. Further disclosed is a combination therapy.